Sichuan medicine how to abandon the "inertia" embrace innovation

06:50 August 20, 2015

Sichuan online - sichuan daily

Our correspondent Zhou Wei

On August 11, composed of 20 CPPCC members "high-end medical equipment and pharmaceutical production situation in our province" research group head into the yasuhiro miyata pharmaceutical, chairman of the board of directors of the company KeZunHong introduction, their companies spend 10 years, independent research and development at a cost of $1 billion, compaq heap, fills the blank of the same drug in domestic, is expected to market imaginary space by billions of dollars in the future.

In stark contrast, one called "effect" of the old proprietary Chinese medicine, there are 792 national pharmaceutical factory in production, including many drug companies in sichuan, in addition to a company is original, the remaining 791 drug firms are generic, and such a huge amount of production led to the drug production overcapacity and vicious competition between the enterprises. "In the hospital bidding only low price bidding policy, under the guide of bargain with each other between enterprises, and even appeared in the price below cost." Enwei group President Xue Yongjiang revealed. "Pharmaceutical r&d can't make me - too (generics), innovation is the way, to lead the sichuan medicine abroad, break the Chinese medicine export embarrassed." The CPPCC members think in succession, the sichuan pharmaceutical industry should take the initiative to adapt to the provincial party committee, provincial government on the implementation of "innovation driven development" strategy, increase investment in scientific research and technology public relations, put an end to low-end production homogeneity, high-end cut into the industry, high-end brand "sichuan medicine".

It is understood that age-related macular degeneration is one of the world's three major blinding factor, in more than 60 people in China more than 10%. Before the advent of compaq heap, drugs have been imported, high cost and high frequency injection. "Monthly need to inject a similar imported drugs, every price is in 10000 yuan, while compaq heap can be 2-3 month injection time, and every price is 6000 yuan, both in cost and curative effect is better than foreign." Yasuhiro miyata relevant person in charge of pharmaceutical group, according to the supporting point of the emerging of new drugs will become the company's future performance.

Research symposium in the day, koren pharmaceutical, biological, mike good doctor medicine etc 10 "medicine" sichuan, head of the leading enterprises have revealed its own ambitions and practical difficulties we are facing. "Drug firms innovation cost and risk is great, new drug research and development will be invested heavily, and the research and development to the world, not ten years eight years come down, and once listed, for the enterprise will lose everything, even may affect the survival of enterprises." The relevant person in charge of south sichuan, biotechnology companies, said clinical examination and approval of new drugs to slow is the bottleneck of pharmaceutical enterprise innovation. Also because of this, causes our country most drug firms are chasing the pace of foreign enterprises, pending patent medicine expires after mass production of generic drugs, gradually formed a "inertia" of the industry.

Happily, these development bottleneck will be readily solved. According to the provincial government "to speed up the development of medicine industry innovation of the implementation opinions", for the first time to get the drugs such as national new drug certificates in sichuan and industrialization, giving the highest reward 5 million yuan; 1, 2 class of investment countries new drug innovation failure, such as research and development of a single project has invested 10 million yuan of above, offer certain risk compensation after that. Aimed at the same time, the whole caliber 2020 pharmaceutical industry scale, 500 billion yuan on the step of goals, "opinions" put forward seven key work plan, involving the joint innovation, technology upgrade and development of traditional Chinese medicine, industry, market circulation, personnel training, opening up and cooperation, etc. As for research and development cycle is long, investment big problem, "the new drug research and development of preclinical and clinical stage created supported by stages, the completion of phase I, II and III clinical trials, respectively according to a certain proportion of the current r&d subsidy."

Fast evaluation of

Let patients to enjoy the well-being of medical innovation

Drugs as a special commodity, compared with other commodities, it to people's health and quality of life has a more important meaning and function. Development of medicine industry, not only affect the enterprise's survival and development, production and sales is about social event in the people's livelihood.

For a long time, because the domestic pharmaceutical industry innovation ability is insufficient, some chronic disease, serious illness caused by poor drug curative effect, have to rely on imported drugs. However, import prices are too high, to increase the great economic burden to patients.

Has caused widespread concern of leukemia patients Liu Yong for themselves and their patients from overseas act as purchasing agency specific's arrest, despite the legal aspects of the problem, on the other side also reflects the unbalanced supply and market demand of the patients. Learned, Liu Yong purchased the goods of medicine called gleevec, is a kind of specific leukemia treatment of CML, due to the domestic patent medicine's price the same as the foreign effect of generic drugs price is one hundred times the price difference, and there is no domestic drug generic drugs, and thus caused the "Liu Yong case".

But, thankfully, compaq heap the advent of new drugs, brought the Gospel to the patients with age-related macular degeneration, "monthly need to inject a similar imported drugs, every price is in 10000 yuan, while compaq heap can be 2-3 month injection time, and every price is 6000 yuan, both in cost and curative effect is better than foreign." Yasuhiro miyata pharmaceutical group of the innovation achievements, listed in less than a year, has brought light and hope for the tens of thousands of patients.

Why there aren't many innovation of new drugs in China? It is understood that due to the drug firms innovation cost and risk is great, maybe will be "pocket", and may even affect the survival of enterprises, this is largely affected drug firms innovation enthusiasm. Face the huge demand for innovative new drugs to market and industry development of golden period of opportunity, the provincial government issued "to speed up the development of medicine industry innovation implementation opinion", decided to get drugs such as national new drug certificates for the first time in sichuan and industrialization, the innovation failure to give cash incentives or risk compensation, encourage enterprises to bold innovation. We believe that the market maker and policy under the escort of shuangli, drug firms in new drugs for patients to provide more cheaper innovation at the same time, will also usher in golden period of its development.

(Yin Xiaohua)